Journal
GEBURTSHILFE UND FRAUENHEILKUNDE
Volume 79, Issue 10, Pages 1079-1089Publisher
GEORG THIEME VERLAG KG
DOI: 10.1055/a-1001-9925
Keywords
breast cancer; adjuvant; neoadjuvant; chemotherapy; antihormone therapy; multigene tests
Categories
Funding
- Hexal
- PRAEGNANT network - Pfizer
- Celgene
- Daiichi Sankyo
- Roche
- Merrimack
- Eisai
- AstraZeneca
- Novartis
Ask authors/readers for more resources
The further development of therapies for women with early breast cancer is progressing far more slowly than in the case of patients with advanced breast cancer and is additionally delayed compared to developments in metastatic breast cancer. Nonetheless, significant advancements have been able to be recorded recently. This review summarises the latest developments in view of the most recent publications and professional conferences. For hormone-receptor-positive patients, new aspects for the duration of antihormone therapy and with regard to the benefits of multigene tests have been published. In the case of HER2-positive patients, the value of post-neoadjuvant therapy and de-escalation of the therapy is discussed. In patients with triple-negative breast cancer, there is a question of whether the knowledge of the biological background of a homologous recombination deficiency (HRD) helps develop new therapies for this subtype. In particular the use of a BRCA1/2 mutation or the biological characteristic HRD as a potential motive for therapy plays a role here in specifying the significance of platinum therapy and therapy with PARP inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available